Precise and sensitive detection of mutation bearing DNA molecules can be critical to drug selection in cancer treatment. For instance, EGFR is an important monitoring target in the treatment of Non-small Cell Lung Carcinoma (NSCLC). Specifically, the presence of EGFR p.T790M mutation indicates tumor resistance to treatment with tyrosine kinase inhibitors (TKIs).1
Integrated DNA Technologies’ rhAmp SNP Genotyping System utilizes RNase H2-depended PCT (rhPCR), a twoenzyme PCR chemistry, which enables highly precise interrogation of SNPs within challenging genomic regions.2 The Combinati Absolute Q digital PCR (dPCR) system utilizes micro-molded plastic picoliter partitions (Figure 1) instead of oil/water emulsions, thus enabling flexibility to accommodate the rhAmp chemistry. For the first time, the IDT rhAmp assay performance was demonstrated on a micro-chamber array based digital PCR platform.
Read More: Download the Application Note
Fill out the form below to be redirected to a downloadable PDF.
- Moran C. (2011). Importance of molecular features of nonsmall cell lung cancer for choice of treatment. The American
journal of pathology, 178(5), 1940–1948. https://doi.org/10.1016/j.
- rhAmp SNP Genotyping System. https://www.idtdna.com/pages/